GSN LIFE SCIENCES was established in 2012 at Hyderabad, a pharmaceutical industrial capital of India. This company was established with a vision to be the globally recognized leader in API intermediates manufacturing, pioneering innovation and excellence to accelerate pharmaceutical advancements.
At GSN LIFE SCIENCES, we are the cornerstone of pharmaceutical development, specializing in the production of high-quality Active Pharmaceutical Ingredient (API) intermediates.With unwavering dedication to precision, innovation, and customer satisfaction, we stand as a trusted partner for the pharmaceutical industry.
Read MoreMake Chemistry Better Together is the motto GSN LIFE SCIENCES stands by. Custom synthesis at GSN LIFE SCIENCES is tailored to meet the customer needs, be it as a laboratory scale-up, commercial scale-up or post commercialisation stages. GSN LIFE SCIECES, as a strategic decision, has chosen to involve itself in the high end and high value additive chemistry research. We offer broad range of standard technologies. We provide advanced synthetic chemistry capabilities and develop molecules from milligram scale to multitoned scale. We always try to work with our customers in flexible, adaptable and customized partnership models. GSN LIFE SCIENCES offers its comprehensive services along with a promise of quality and consistency. These are made available at a speed and cost that are mutually beneficial. Our facilities are equipped with the latest process and analytical instrumentation. As well as an extensive range of scale-up equipment and key areas of expertise, our scientists have the experience and professionalism to move your projects forward.
Pharmaceutical products consist of active ingredients, which are combined with additional materials (excipients) selected to control dosage delivery, enhance performance and facilitate manufacture. The synthesis of processes for the production of the active ingredient, especially for small molecule substances, is a classical reaction path selection and process synthesis problem but is made more challenging because of the need for impurity minimization.
We are in a new era of medicine where breakthrough science is transforming care and our approach to treating patients. Robust investment in research and development (R&D) by biopharmaceutical companies is resulting in advances and discoveries unlike anything we’ve seen before. The application of genomics to develop personalized medicines is enabling physicians to tailor treatments to the unique needs of the patient.
The specifics of the product design subproblem will, of course, differ depending on the product form, for instance, solid oral, injectable, or topical. While pharmaceutical product design is at root a formulation design problem it is complicated by the constraints imposed by the manufacturing operations, the need to facilitate patient compliance and the requirements for achieving desired therapeutic performance.
Phenol, 2,2′-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-ethylhexyl)oxy] Bemotrizinol
1,3-Diazaspiro[4.4]non-1-en-4-one, 3-[[4-bromo-3-(ethoxymethyl)phenyl]methyl]-2-butyl-, ethanedioate (1:2)
(βR)-4-Bromo-β-cyclopentyl-1H-pyrazole-1-propanenitrile
(2S)-1,4-Dioxaspiro[4.5]decane-2-methanol
Ethyl isocyanatoacetate
1,1,1-Trimethoxyoctane
